As of Nov 10, 2018 Tenax Therapeutics Inc (NASDAQ:TENX) Sellers Declined Their Shorts By 3.01%

Tenax Therapeutics Inc (NASDAQ:TENX) had a decrease of its short interest by 3.01%. FINRA issued in November TENX’s total 96,700 short interest. The 99,700 previous shares are down with 3.01%. With Average volume 5,100, TENX’s former position will take 19 days to restore. Tenax Therapeutics Inc’s short interest float is 8.67%.

TENX hit $4.05 during the last trading session after $0.24 change.Tenax Therapeutics, Inc. has 18,799 shares volume, 110.07% up from normal. TENX is downtrending and has moved 25.18% since November 10, 2017. TENX underperformed the S&P 500 by 40.80%.

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada.The firm is valued at $5.94 million. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome.Last it reported negative earnings. The firm was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014.

A couple more Tenax Therapeutics, Inc. (NASDAQ:TENX) news were announced by: Benzinga.com which released on November 08, 2018 “88 Biggest Movers From Yesterday”, also Seekingalpha.com on November 07, 2018 announced “Tenax Therapeutics readies equity offering”, the next Benzinga.com is “The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz’ Voluntary Recall” on November 09, 2018. Benzinga.com has article titled “The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.